IMJUDO (tremelimumab)

**Product type:** Human Prescription Drug

**Active ingredient:** TREMELIMUMAB

**Strength:** 300 mg/15mL

**Dosage form:** Injection, Solution

**Route:** Intravenous

**Labeler:** AstraZeneca Pharmaceuticals LP

**Marketing category:** BLA (BLA761289)

**Pharmacologic class:** CTLA-4-directed Antibody Interactions [MoA], CTLA-4-directed Blocking Antibody [EPC], Increased T Lymphocyte Activation [PE]